Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The cost of HIV medication adherence support interventions: results of a cross-site evaluation.

Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L; CENTER FOR ADHERENCE SUPPORT AND EVALUATION (CASE) TEAM.

AIDS Care. 2005 Nov;17(8):927-37.

PMID:
16265786
2.

Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus.

Munakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce JC.

Med Care. 2006 Oct;44(10):893-9.

PMID:
17001259
3.

Cost-effectiveness of clinical interventions for AIDS wasting.

Beaston-Blaakman A, Shepard DS, Stone N, Shevitz AH.

AIDS Care. 2007 Sep;19(8):996-1001.

PMID:
17851996
4.

Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.

Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL.

J Ment Health Policy Econ. 2009 Mar;12(1):33-46.

PMID:
19346565
5.

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

N Engl J Med. 2005 Feb 10;352(6):570-85.

6.

The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

Krentz HB, Auld MC, Gill MJ; HIV Economic Study Group.

CMAJ. 2003 Jul 22;169(2):106-10.

7.

Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients, Francistown, Botswana.

Moalosi G, Floyd K, Phatshwane J, Moeti T, Binkin N, Kenyon T.

Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S80-5.

PMID:
12971658
8.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
9.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
10.

The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.

Marseille E, Saba J, Muyingo S, Kahn JG.

AIDS. 2006 Apr 4;20(6):907-14.

PMID:
16549976
11.

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.

Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR 3rd, Kimmel AD, Walensky RP, Sax PE, Freedberg KA.

Am J Med. 2003 Dec 1;115(8):632-41.

PMID:
14656616
12.
13.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
14.

Costs and effectiveness of substance abuse treatments for homeless persons.

Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K.

J Ment Health Policy Econ. 2002 Mar;5(1):33-42.

PMID:
12529568
15.

[Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil].

Acurcio Fde A, Puig-Junoy J, Bonolo Pde F, Braga Ceccato Md, GuimarĂ£es MD.

Rev Esp Salud Publica. 2006 Jan-Feb;80(1):41-54. Spanish.

16.

Indirect cost of HIV infection in England.

Mullins CD, Whitelaw G, Cooke JL, Beck EJ.

Clin Ther. 2000 Nov;22(11):1333-45.

PMID:
11117658
17.

Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.

Krentz HB, Gill MJ.

HIV Med. 2008 Oct;9(9):721-30. doi: 10.1111/j.1468-1293.2008.00613.x. Epub 2008 Jul 17.

18.
19.

Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients.

Lamiraud K, Moatti JP.

Expert Opin Pharmacother. 2006 Feb;7(2):135-43. Review.

PMID:
16433579
20.

Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.

Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, Hellinger J, Rutstein R, Keiser P, Rubin H, Moore RD; HIV Research Network.

Med Care. 2005 Sep;43(9 Suppl):III40-52.

PMID:
16116308

Supplemental Content

Support Center